WEBULL
WebtradeDownload

BioNTech (BNTX) Halts Cancer Trial, Is The 15% Undervaluation Still Credible?

Simply Wall St · 3d ago

BioNTech (NasdaqGS:BNTX) has halted a Phase 2 trial of its individualized mRNA cancer immunotherapy autogene cevumeran in high risk colorectal cancer after an independent Data Safety Monitoring Board recommended stopping the study for futility.

BioNTech’s recent news flow mixes setbacks and progress, with the termination of this colorectal cancer trial arriving shortly after fresh lung cancer data and an FDA approval for the updated COMIRNATY XFG COVID-19 vaccine. The 7 day share price return of a 10.61% decline and 30 day share price return of a 12.55% gain, together with a 1 year total shareholder return of 1.32%, suggest choppy momentum after a much weaker 5 year total shareholder return, during which investors experienced a 70.30% decline.

Look beyond BioNTech and see how other healthcare stocks with strong balance sheets and fundamentals are setting up right now through our curated list of solid balance sheet and fundamentals (53 results).

Bulls see BioNTech as a cash rich mRNA platform that is underpriced after heavy long term share price losses. Bears focus on oncology setbacks and current losses. Which side does the current valuation really support next?

Most Popular Narrative: 15.5% Undervalued

BioNTech's most followed narrative pegs fair value at $120.62 compared with a last close of $101.95. This frames the stock as modestly undervalued and heavily dependent on how its oncology and mRNA platforms play out.

Robust pipeline expansion in oncology with multiple late-stage (Phase II and Phase III) clinical trials for BNT327 and mRNA cancer immunotherapies across high-prevalence cancers (lung and breast) positions BioNTech to launch multiple new products, driving significant top-line revenue growth and enhancing earnings visibility over the next several years. Deep investment and advances in mRNA platform technologies, supported by the planned CureVac acquisition and expanding R&D infrastructure, enhance BioNTech's ability to penetrate the rapidly growing market for personalized medicine targeting expanding patient populations and supporting long-term margin expansion.

Read the complete narrative.

Want to see what is baked into that $120.62 fair value for BioNTech? The narrative leans on shrinking revenues, rising margins and a rich future earnings multiple. Curious which exact profitability path and share count assumptions sit behind that bullish model? The full breakdown lays out every step.

Result: Fair Value of $120.62 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the BioNTech narrative could unravel if oncology trials stumble or if extended legal disputes around COVID 19 vaccine technology weigh on future cash flows.

Find out about the key risks to this BioNTech narrative.

Next Steps

Looking for more ideas beyond BioNTech?

Do not stop at BioNTech. Use the Simply Wall Street Screener to uncover fresh, data driven stock ideas that might fit your portfolio and risk profile better.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.